Researchers are developing what they hope will be the first successful vaccine against the highly contagious and difficult-to ...

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

The discovery of the first mRNA-stabilizing substance could pave the way for groundbreaking advancements in the development ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

Study reveals single-chain mRNA vaccines confer 100% protection against lethal mpox challenge in mice, marking a significant ...

An 800% increase in licensing deal values indicates growing confidence in mRNA technology, but some vaccine producers are ...

In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new ...

We recently compiled a list of the 10 Worst Performing NASDAQ Stocks in 2024. In this article, we are going to take a look at ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

Experts hope the Moderna jab could stop people developing the vomiting and diarrhoea bug, which is linked to around 12,000 ...